IMV Inc. announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S, or MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma, or r/r DLBCL. Key initial findings from the ongoing VITALIZE trial: eight patients with an ECOG1 score of 0-1 have been enrolled in arm 1 of the study. Of these, 6 have so far been evaluable for efficacy; of these six evaluable patients, three patients showed confirmed complete responses, one patient was assessed with stable disease as best response and two patients were assessed with progressive disease as best response and two patients with poor level of baseline functionality failed to stay on study through to the first scan and therefore could not be evaluated. Overall Response Rate will be communicated when the totality of stage one data are available for definitive assessment.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMV:
- IMV Inc. target adjusted to $65 for split at H.C. Wainwright
- Biotech Alert: Searches spiking for these stocks today
- IMV Inc. announces $9M registered direct offering priced ATM
- IMV Blasts Up after New Test Data Emerges
- IMV Inc. to present initial patient data from VITALIZE trial
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue